Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function

Cardiovascular Diabetology

Chih-Hong Wang¹  Ta-Yu Liu¹  Wen-Han Chuang¹  Hendra Susanto¹  Chang-Chiang Chen² 

[1] Department of Biological Science and Technology, National Chiao Tung University, 75 Bo-Ai Street, Hsinchu 300, Taiwan;Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu 300, Taiwan

关键词: eGFR;    ACR;    Diabetic nephropathy;    Type 2 diabetes;    Betatrophin;   

Others  :  1235270
DOI  :  10.1186/s12933-015-0326-9

 received in 2015-10-01, accepted in 2015-12-28,  发布年份 2016

【 摘 要 】

Background

Betatrophin is a newly identified liver-derived hormone that is associated with glucose homeostasis and lipid metabolism. Although dysregulated lipid metabolism results in diabetic nephropathy (DN) development in patients with type 2 diabetes mellitus (T2DM), it is not understood whether betatrophin is associated with urinary albumin excretion and renal function.

Methods

Based on albumin/creatinine ratio (ACR), 109 T2DM patients were divided into normoalbuminuria (ACR <30 mg/g), microalbuminuria (ACR between 30 and 300 mg/g), and macroalbuminuria (ACR > 300 mg/g). Serum betatrophin levels of 109 T2DM patients and 32 healthy subjects were determined by enzyme-linked immunosorbent assay (ELISA).

Results

Serum level of betatrophin was significantly increased in T2DM patients with normoalbuminuria, microalbuminuria, and macroalbuminuria as compared with healthy subjects (P < 0.001). Serum betatrophin level was positively correlated with sex, duration of diabetes, systolic blood pressure (SBP), body mass index (BMI), ACR, and triglyceride, whereas it was inversely correlated with estimated glomerular filtration rate (eGFR), total cholesterol, and high-density lipoprotein cholesterol (HDL-C) (P < 0.001). Furthermore, multivariate regression analysis showed the betatrophin was significantly and positively independent with triglyceride and low-density lipoprotein cholesterol (LDL-C) (P < 0.05), whereas it was inversely independent with eGFR, total cholesterol, and low-density lipoprotein cholesterol (HDL-C) (P < 0.05). In addition, the betatrophin had higher odds of having DN [odds ratio (OR) = 5.65, 95 % confidence interval (CI) 2.17–14.57, P < 0.001].

Conclusion

Betatrophin is significantly increased in T2DM patients with different stages of albuminuria. Betatrophin may be a novel endocrine regulator involved in DN development.

【 授权许可】

   
2016 Chen et al.

【 图 表 】

Fig.1.

Fig.2.

【 参考文献 】

• [1]Dinesh Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet. 2015;385(suppl 1):S86.
• [2]Svensson M, Eriksson JW. Insulin resistance in diabetic nephropathy–cause or consequence? Diabetes Metab Res Rev. 2006; 22:401-410.
• [3]Hadjadj S, Pean F, Gallois Y, Passa P, Aubert R, Weekers L et al.. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the genesis France–Belgium Study. Diabetes Care. 2004; 27:2661-2668.
• [4]Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol. 2014; 2014:323407.
• [5]Tessari P, Kiwanuka E, Millioni R, Vettore M, Puricelli L, Zanetti M et al.. Albumin and fibrinogen synthesis and insulin effect in type 2 diabetic patients with normoalbuminuria. Diabetes Care. 2006; 29:323-328.
• [6]Jang CM, Hyun YY, Lee KB, Kim H. Insulin resistance is associated with the development of albuminuria in Korean subjects without diabetes. Endocrine. 2015; 48:203-210.
• [7]Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC, Hobbs HH. Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci USA. 2013; 110:16109-16114.
• [8]Chen X, Lu P, He W, Zhang J, Liu L, Yang Y et al.. Circulating betatrophin levels are increased in patients with type 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab. 2015; 100:E96-E100.
• [9]Yamada H, Saito T, Aoki A, Asano T, Yoshida M, Ikoma A, et al. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J. 2015.
• [10]Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013; 153:747-758.
• [11]Espes D, Lau J, Carlsson PO. Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia. 2014; 57:50-53.
• [12]Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2014; 4:5013.
• [13]Zhang R, Abou-Samra AB. A dual role of lipasin (betatrophin) in lipid metabolism and glucose homeostasis: consensus and controversy. Cardiovasc Diabetol. 2014; 13:133. BioMed Central Full Text
• [14]Fenzl A, Itariu BK, Kosi L, Fritzer-Szekeres M, Kautzky-Willer A, Stulnig TM et al.. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014; 57:1204-1208.
• [15]Gomez-Ambrosi J, Pascual E, Catalan V, Rodriguez A, Ramirez B et al.. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014; 99:E2004-E2009.
• [16]Ebert T, Kralisch S, Hoffmann A, Bachmann A, Lossner U, Kratzsch J et al.. Circulating angiopoietin-like protein 8 is independently associated with fasting plasma glucose and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2014; 99:E2510-E2517.
• [17]Hu H, Sun W, Yu S, Hong X, Qian W, Tang B et al.. Increased circulating levels of betatrophin in newly diagnosed type 2 diabetic patients. Diabetes Care. 2014; 37:2718-2722.
• [18]Erol O, Ellidag HY, Ayik H, Ozel MK, Derbent AU, Yilmaz N. Evaluation of circulating betatrophin levels in gestational diabetes mellitus. Gynecol Endocrinol. 2015; 31:652-656.
• [19]Yamada H, Saito T, Aoki A, Asano T, Yoshida M, Ikoma A et al.. Circulating betatrophin is elevated in patients with type 1 and type 2 diabetes. Endocr J. 2015; 62:417-421.
• [20]Fujikawa R, Okubo M, Egusa G, Kohno N. Insulin resistance precedes the appearance of albuminuria in non-diabetic subjects: 6 years follow-up study. Diabetes Res Clin Pract. 2001; 53:99-106.
• [21]Fu Z, Abou-Samra AB, Zhang R. An explanation for recent discrepancies in levels of human circulating betatrophin. Diabetologia. 2014; 57:2232-2234.
• [22]Abu-Farha M, Abubaker J, Al-Khairi I, Cherian P, Noronha F, Hu FB et al.. Higher plasma betatrophin/ANGPTL8 level in Type 2 diabetes subjects does not correlate with blood glucose or insulin resistance. Sci Rep. 2015; 5:10949.
• [23]Abu-Farha M, Abubaker J, Noronha F, Al-Khairi I, Cherian P, Alarouj M et al.. Lack of associations between betatrophin/ANGPTL8 level and C-peptide in type 2 diabetic subjects. Cardiovasc Diabetol. 2015; 14:112. BioMed Central Full Text
• [24]De Tata V. Age-related impairment of pancreatic Beta-cell function: pathophysiological and cellular mechanisms. Front Endocrinol (Lausanne). 2014; 5:138.
• [25]Guo K, Lu J, Yu H, Zhao F, Pan P, Zhang L et al.. Serum betatrophin concentrations are significantly increased in overweight but not in obese or type 2 diabetic individuals. Obesity (Silver Spring). 2015; 23:793-797.
• [26]McKay GJ, Savage DA, Patterson CC, Lewis G, McKnight AJ, Maxwell AP et al.. Association analysis of dyslipidemia-related genes in diabetic nephropathy. PLoS One. 2013; 8:e58472.
• [27]Lezcano EJ, Inigo P, Larraga AM, Barranquero C, Gimenez I, Osada J. Caloric restriction or telmisartan control dyslipidemia and nephropathy in obese diabetic Zucker rats. Diabetol Metab Syndr. 2014; 6:10. BioMed Central Full Text
• [28]Thomas MC, Rosengard-Barlund M, Mills V, Ronnback M, Thomas S, Forsblom C et al.. Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care. 2006; 29:317-322.
• [29]Krolewski AS, Warram JH, Christlieb AR. Hypercholesterolemia—a determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int Suppl. 1994; 45:S125-S131.
• [30]Mangili R, Zerbini G, Barlassina C, Cusi D, Pozza G. Sodium-lithium countertransport and triglycerides in diabetic nephropathy. Kidney Int. 1993; 44:127-133.
• [31]Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des. 2008; 14:946-952.
• [32]Zhang MH, Feng L, Zhu MM, Gu JF, Jiang J, Cheng XD et al.. The anti-inflammation effect of Moutan Cortex on advanced glycation end products-induced rat mesangial cells dysfunction and high-glucose-fat diet and streptozotocin-induced diabetic nephropathy rats. J Ethnopharmacol. 2014; 151:591-600.
• [33]Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007; 27:130-143.
• [34]Zhang R, Abou-Samra AB. Emerging roles of Lipasin as a critical lipid regulator. Biochem Biophys Res Commun. 2013; 432:401-405.
• [35]Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012; 424:786-792.